Risk of a secondary neoplasm associated with chemotherapeutic agents
| Therapeutic Elements . | Number of Patients (%) . | Number of SN . | Cumulative Incidence after 15 Years (95% CI) . |
|---|---|---|---|
| Anthracycline dose (f) | P = .11 | ||
| ≤ 240 mg/m2 | 3965 (79.2) | 37 | 3.0% (1.1%-4.9%) |
| > 240 mg/m2 | 1041 (20.8) | 9 | 1.2% (0%-2.5%) |
| Anthracycline dose (+r) | P = .38 | ||
| ≤ 240 mg/m2 | 3147 (62.9) | 3715 | 3.9% (2.0%-5.8%) |
| > 240 mg/m2 | 1859 (37.1) | 2.2% (0%-5.6%) | |
| Epipodophyllotoxin (f) | P = .99 | ||
| No | 4527 (90.4) | 37 | 2.8% (0.9%-4.7%) |
| Yes | 479 (9.6) | 9 | 2.8% (0%-6.6%) |
| Epipodophyllotoxin (+r) | P = .42 | ||
| No | 3569 (71.3) | 3715 | 3.7% (1.8%-5.5%) |
| Yes | 1437 (28.7) | 2.1% (0%-5.4%) | |
| Cyclophosphamide (f) | P = .45 | ||
| ≤ 3000 mg/m2 | 4584 (91.6) | 39 | 3.1% (0.9%-5.2%) |
| > 3000 mg/m2 | 422 (8.4) | 7 | 1.9% (0-4%.1%) |
| Cyclophosphamide (+r) | P = .14 | ||
| ≤ 3000 mg/m2 | 3560 (71.1) | 3913 | 4.1% (1.9%-6.2%) |
| > 3000 mg/m2 | 1446 (28.9) | 1.6% (0%-4.1%) |
| Therapeutic Elements . | Number of Patients (%) . | Number of SN . | Cumulative Incidence after 15 Years (95% CI) . |
|---|---|---|---|
| Anthracycline dose (f) | P = .11 | ||
| ≤ 240 mg/m2 | 3965 (79.2) | 37 | 3.0% (1.1%-4.9%) |
| > 240 mg/m2 | 1041 (20.8) | 9 | 1.2% (0%-2.5%) |
| Anthracycline dose (+r) | P = .38 | ||
| ≤ 240 mg/m2 | 3147 (62.9) | 3715 | 3.9% (2.0%-5.8%) |
| > 240 mg/m2 | 1859 (37.1) | 2.2% (0%-5.6%) | |
| Epipodophyllotoxin (f) | P = .99 | ||
| No | 4527 (90.4) | 37 | 2.8% (0.9%-4.7%) |
| Yes | 479 (9.6) | 9 | 2.8% (0%-6.6%) |
| Epipodophyllotoxin (+r) | P = .42 | ||
| No | 3569 (71.3) | 3715 | 3.7% (1.8%-5.5%) |
| Yes | 1437 (28.7) | 2.1% (0%-5.4%) | |
| Cyclophosphamide (f) | P = .45 | ||
| ≤ 3000 mg/m2 | 4584 (91.6) | 39 | 3.1% (0.9%-5.2%) |
| > 3000 mg/m2 | 422 (8.4) | 7 | 1.9% (0-4%.1%) |
| Cyclophosphamide (+r) | P = .14 | ||
| ≤ 3000 mg/m2 | 3560 (71.1) | 3913 | 4.1% (1.9%-6.2%) |
| > 3000 mg/m2 | 1446 (28.9) | 1.6% (0%-4.1%) |
SN: secondary neoplasm; f: frontline therapy, sek.mal. as first event; +r: frontline + relapse therapy.